Table 3.
Results of multivariate analysis for nonrelapse mortality, relapse, and overall mortality
| Outcome | No. of events/no. evaluable | HR (95% CI) | P |
|---|---|---|---|
| Nonrelapse mortality* | |||
| MSD/PS ≥90 | 277/883 | 1.00 | |
| MUD/PS ≥90 | 151/441 | 1.42 (1.15-1.74) | .001 |
| MSD/PS ≤80 | 199/477 | 1.00 | |
| MUD/PS ≤80 | 84/222 | 0.96 (0.74-1.24) | .76 |
| Relapse† | |||
| MSD/PS ≥90 | 252/883 | 1.00 | |
| MUD/PS ≥90 | 167/441 | 1.57 (1.29-1.91) | <.001 |
| MSD/PS ≤80 | 179/477 | 1.00 | |
| MUD/PS ≤80 | 81/222 | 0.86 (0.66-1.12) | .25 |
| Overall mortalityठ| |||
| MSD/PS ≥90 | 479/883 | 1.00 | |
| MUD/PS ≥90 | 293/441 | 1.66 (1.45-1.91) | <.001 |
| MSD/PS ≤80 | 358/477 | 1.00 | |
| MUD/PS ≤80 | 160/222 | 0.90 (0.75-1.09) | .29 |
| Treatment failure|| | |||
| MSD/PS ≥90 | 529/883 | 1.00 | |
| MUD/PS ≥90 | 318/441 | 1.63 (1.43-1.87) | <.001 |
| MSD/PS ≤80 | 378/477 | 1.00 | |
| MUD/PS ≤80 | 165/222 | 0.88 (0.73-1.06) | .18 |
PS, [patient] performance score.
*
Model adjusted for disease status, conditioning regimen, donor-recipient sex match, and GVHD prophylaxis.
†
Model adjusted for disease, disease status, conditioning regimen, and transplantation period.
‡
Model for overall mortality stratified by conditioning regimen.
§
Model adjusted for patient age, disease, and disease status.
||
Model adjusted for disease, disease status, and in vivo T-cell depletion.